CN108029865A - A kind of quinocetone premix - Google Patents
A kind of quinocetone premix Download PDFInfo
- Publication number
- CN108029865A CN108029865A CN201711187256.8A CN201711187256A CN108029865A CN 108029865 A CN108029865 A CN 108029865A CN 201711187256 A CN201711187256 A CN 201711187256A CN 108029865 A CN108029865 A CN 108029865A
- Authority
- CN
- China
- Prior art keywords
- quinocetone
- groups
- premix
- test
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
Abstract
The invention discloses a kind of quinocetone premix, it includes quinocetone and alkaline kation compound；Since the side chain of quinocetone is the macromolecular of a benzene ring structure, this structure can ensure the integrality of quinocetone molecule in animal body, but can spatially hinder the combination of quinocetone and pathogen so that the action effect of quinocetone cannot play completely；Add distribution of charges of the alkaline kation compound by adjusting pathogen, combined with quinocetone to pathogen presentation property, strengthen the restraining and sterilizing bacteria ability of quinocetone, effectively overcome the shortcomings that quinocetone action effect is unstable, so that more notable to the effect for preventing animal diarrhea disease；It is further to promote growth of animal and reduce feedstuff-meat ratio meanwhile quinocetone and alkaline kation compound have synergistic effect.
Description
Technical field
The present invention relates to field of veterinary, and in particular to a kind of quinocetone premix.
Background technology
With the development of science and technology, scientific culture is increasingly focused in cultivation, under the premise of healthy aquaculture is ensured, pass through addition one
A little medicines improve animal disease resistant power, promote growth of animal, reduce feedstuff-meat ratio, improve food conversion ratio, and it is common to become modern cultivation
Means.
It is used to treat in cultivation at present to improve animal disease resistant power, the medicine for promoting growth of animal is mainly quinocetone.Quinoline alkene
The chemical name of ketone is 3- methyl -2- cinnamoyl quinoxaline-Isosorbide-5-Nitrae-dioxide (abbreviation MBQO), is evaluated through national basic veterinary drug
Do a kind of safe and environment-friendly health, the medicated feed additive of new high-efficiency of identification.Quinocetone has gram-positive bacteria very strong
Activity, it is particularly very strong to harmful clostridium restraint of enteral, be not easy to develop immunity to drugs after long-time service, have
There is the bacterial flora effect changed in enteron aisle.Experiment prove quinocetone to lifted Animal diseases prevention and control ability, improve food conversion ratio,
Improve livestock and poultry meat quality, promote growth, increase culture benefit, be of great significance.Although quinocetone has many advantages, such as, its
There are still act on the shortcomings of unstable.
The content of the invention
It is an object of the invention to overcome above-mentioned technical deficiency, there is provided a kind of quinocetone premix, solves in the prior art
The unstable technical problem of quinocetone action effect.
The present invention provides a kind of quinocetone premix, it includes quinocetone and alkaline kation compound.
Alkaline kation compound (Ionized Alkali Mineral Complex, abbreviation IAMC), is a kind of high property
Energy alkaline kation physiological activity conditioning agent, it is a kind of ionic compound, includes the elements such as lanthanum, cerium, praseodymium, neodymium and samarium.
Compared with prior art, beneficial effects of the present invention include：
The active ingredient for the quinocetone premix that the technical program provides is quinocetone and alkaline kation compound, due to
The side chain of quinocetone is the macromolecular of a benzene ring structure, and this structure can ensure quinocetone molecule in animal body complete
Property, but can spatially hinder the combination of quinocetone and pathogen so that the action effect of quinocetone cannot play completely；Add
Alkaline kation compound is combined to pathogen presentation property with quinocetone by adjusting the distribution of charges of pathogen, strengthens quinoline alkene
The restraining and sterilizing bacteria ability of ketone, further enhancing the killing effect to Gram-negative bacteria, effectively overcome quinocetone effect
The shortcomings that effect is unstable, so that more notable to the effect for preventing animal diarrhea disease；Meanwhile quinocetone and alkaline kation
Compound has synergistic effect, further to promote growth of animal and reduce feedstuff-meat ratio.
Embodiment
A kind of quinocetone premix is present embodiments provided, specifically, it includes quinocetone and alkaline kation compound,
The alkaline kation compound (Ionized Alkali Mineral Complex, abbreviation IAMC), is a kind of performance alkali
Property cation physiological activity conditioning agent, it is a kind of ionic compound, includes the elements such as lanthanum, cerium, praseodymium, neodymium and samarium.
Specifically, it further includes pharmaceutic adjuvant, it is preferable that the pharmaceutic adjuvant is precipitated calcium carbonate.
Specifically, the percentage by weight of the quinocetone is 5%~25%, the percentage by weight of alkaline kation compound
For 0.2%~5%, surplus is pharmaceutic adjuvant.
Preferably, the percentage by weight of the quinocetone is 5% or 25%, the percentage by weight of alkaline kation compound
For 0.2%~5%, surplus is pharmaceutic adjuvant.
The present embodiment additionally provides the preparation method of above-mentioned quinocetone premix, specific as follows：By weight percentage, claim
The percentage by weight for taking quinocetone is 5%~25%, and the percentage by weight of alkaline kation compound is 0.2%~5%, surplus
For precipitated calcium carbonate；Preferably, the percentage by weight for weighing quinocetone is 5% or 25%, the weight of alkaline kation compound
It is 0.2%~5% to measure percentage, and surplus is precipitated calcium carbonate；By the above-mentioned quinocetone weighed, alkaline kation compound and light
Matter calcium carbonate is together put into mixer and is uniformly mixed, up to quinocetone premix.
Quinocetone premix foundation manufactured in the present embodiment《Veterinary medical quality standard》Requirement method detect above-mentioned quinocetone
The quality of quinocetone in pre-mixing agent, indices meet regulation.
Quinocetone premix provided by the invention and preparation method thereof is given further below in conjunction with specific embodiment
Explanation.The embodiments described below is exemplary, and is only used for explaining the present invention, and is not considered as limiting the invention.
Experiment material used is that market is commercially available unless otherwise specified in following embodiments.
Embodiment 1：
The embodiment provides a kind of quinocetone premix, wherein：Quinocetone content is 5%, and alkaline kation compound contains
Measure as 0.2%, precipitated calcium carbonate content is 94.8%.The preparation method of the present embodiment quinocetone premix, it is specific as follows：
Weigh 50g quinocetones, 2g alkaline kation compounds, 948g precipitated calcium carbonates；By the above-mentioned quinocetone weighed, alkali
Property cationic compound and precipitated calcium carbonate be together put into mixer be uniformly mixed, up to 1kg quinocetone premixes.
Foundation《Veterinary medical quality standard》Requirement method detect the quality of quinocetone in above-mentioned quinocetone premix, items refer to
Mark meets regulation.
The effect experiment of the present embodiment quinocetone premix：For the clinic of the quinocetone premix of the objective appraisal present invention
Effect, it is control drug to select folk prescription quinocetone medicine, is tested on piglet.
1. materials and methods
1.1 experimental animal：
28 ± 2 age in days weanling pig 90 similar in health, physique.
1.2 experiment packets and method：
3 groups are randomly divided into after 90 piglets every are weighed, every group 30, the test period is 28 days.Experiment packet is set
Put and handle and is as follows：
Control group：30 piglets, only feed basal feed；
Test I groups：30 piglets, feed the folk prescription quinocetone premix 1kg of basal feed+5%；
Test II groups：30 piglets, feed the quinocetone premix 1kg of basal feed+the present embodiment；
2. result of the test
Record the result of 3 test groups and carry out statistical analysis, result of the test is shown in Tables 1 and 2, tries as can be seen from Table 1
Test I groups and the experiment increased weight of II group piglets is above control group, feedstuff-meat ratio is below control group, but tests the effect of II groups
It is more notable；The diarrhea rate for testing I groups and experiment II group piglets as can be seen from Table 2 is below control group, but tests II groups
Effect is more notable.Illustrate that quinocetone premix provided in this embodiment is significantly reduced effect to the diarrhea rate of weanling pig
And the production performance of piglet can be further improved.
Influence of 1 quinocetone of table to piglet growth performance
| Group | Initial weight, kg | End weight, kg | Average daily gain, g | Average daily gain, g | Feedstuff-meat ratio |
| Control group | 8.22 | 16.45A | 293A | 502 | 1.71A |
| Test I groups | 8.24 | 16.74B | 304B | 504 | 1.66B |
| Test II groups | 8.23 | 16.90C | 310C | 498 | 1.61C |
| SEM | 0.08 | 0.1 | 8 | 10 | 0.03 |
Note：A, B, C same column difference capitalization represent significant difference (P<0.05), no letter or the identical expression of letter
Difference is not notable (P ＞ 0.05)；Following table is same.
Influence of 2 quinocetone of table to grice diarrhoea rate
Embodiment 2：
The embodiment provides a kind of quinocetone premix, wherein：Quinocetone content is 5%, and alkaline kation compound contains
Measure as 0.5%, precipitated calcium carbonate content is 94.5%.The preparation method of the present embodiment quinocetone premix, it is specific as follows：
Weigh 50g quinocetones, 5g alkaline kation compounds, the precipitated calcium carbonate of 945g；By the above-mentioned quinocetone weighed,
Alkaline kation compound and precipitated calcium carbonate are together put into mixer and are uniformly mixed, up to 1kg quinocetone premixes.
Foundation《Veterinary medical quality standard》Requirement method detect the quality of quinocetone in above-mentioned quinocetone premix, items refer to
Mark meets regulation.
The effect experiment of the present embodiment quinocetone premix：
1. experimental animal, experiment are grouped and the test period is with embodiment 1, wherein：
Control group：30 piglets, only feed basal feed；
Test I groups：30 piglets, feed the folk prescription quinocetone premix 1kg of basal feed+5%；
Test II groups：30 piglets, feed the quinocetone premix 1kg of basal feed+the present embodiment；
2. result of the test
Record the result of 3 test groups and carry out statistical analysis, result of the test is shown in Table 3 and table 4, tries as can be seen from Table 3
Test I groups and the experiment increased weight of II group piglets is above control group, feedstuff-meat ratio is below control group, but tests the effect of II groups
It is more notable；The diarrhea rate for testing I groups and experiment II group piglets as can be seen from Table 4 is below control group, but tests II groups
Effect is more notable.Illustrate that quinocetone premix provided in this embodiment is significantly reduced effect to the diarrhea rate of weanling pig
And the production performance of piglet can be further improved.
Influence of 3 quinocetone of table to piglet growth performance
| Group | Initial weight, kg | End weight, kg | Average daily gain, g | Average daily gain, g | Feedstuff-meat ratio |
| Control group | 8.22 | 16.45A | 293A | 502 | 1.71A |
| Test I groups | 8.24 | 16.74B | 304B | 504 | 1.66B |
| Test II groups | 8.24 | 17.44C | 329C | 500 | 1.52C |
| SEM | 0.08 | 0.1 | 8 | 10 | 0.03 |
Influence of 4 quinocetone of table to grice diarrhoea rate
| Group | Head number | Diarrhea rate, % |
| Control group | 30 | 4.94A |
| Test I groups | 30 | 4.87B |
| Test II groups | 30 | 4.49C |
| SEM | 0.06 |
Embodiment 3：
The embodiment provides a kind of quinocetone premix, wherein：Quinocetone content is 5%, and alkaline kation compound contains
Measure as 1%, precipitated calcium carbonate content is 94%.The preparation method of the present embodiment quinocetone premix, it is specific as follows：
Weigh 50g quinocetones, 10g alkaline kation compounds, the precipitated calcium carbonate of 940g；By the above-mentioned quinoline alkene weighed
Ketone, alkaline kation compound and precipitated calcium carbonate are together put into mixer and are uniformly mixed, up to 1kg quinocetone premixes.
Foundation《Veterinary medical quality standard》Requirement method detect the quality of quinocetone in above-mentioned quinocetone premix, items refer to
Mark meets regulation.
The effect experiment of the present embodiment quinocetone premix：
1. experimental animal, experiment are grouped and the test period is with embodiment 1, wherein：
Control group：30 piglets, only feed basal feed；
Test I groups：30 piglets, feed the folk prescription quinocetone premix 1kg of basal feed+5%；
Test II groups：30 piglets, feed the quinocetone premix 1kg of basal feed+the present embodiment；
2. result of the test
Record the result of 3 test groups and carry out statistical analysis, result of the test is shown in Table 5 and table 6, tries as can be seen from Table 5
Test I groups and the experiment increased weight of II group piglets is above control group, feedstuff-meat ratio is below control group, but tests the effect of II groups
It is more notable；The diarrhea rate for testing I groups and experiment II group piglets as can be seen from Table 6 is below control group, but tests II groups
Effect is more notable.Illustrate that quinocetone premix provided in this embodiment is significantly reduced effect to the diarrhea rate of weanling pig
And the production performance of piglet can be further improved.
Influence of 5 quinocetone of table to piglet growth performance
Influence of 6 quinocetone of table to grice diarrhoea rate
| Group | Head number | Diarrhea rate, % |
| Control group | 30 | 4.94A |
| Test I groups | 30 | 4.87B |
| Test II groups | 30 | 4.46C |
| SEM | 0.06 |
Embodiment 4：
The embodiment provides a kind of quinocetone premix, wherein：Quinocetone content is 25%, and alkaline kation compound contains
Measure as 1%, precipitated calcium carbonate content is 74%.The preparation method of the present embodiment quinocetone premix, it is specific as follows：
Weigh 62.5g quinocetones, 2.5g alkaline kation compounds, the precipitated calcium carbonate of 185g；By the above-mentioned quinoline weighed
Ketenes, alkaline kation compound and precipitated calcium carbonate are together put into mixer and are uniformly mixed, and are premixed up to 250g quinocetones
Agent.
Foundation《Veterinary medical quality standard》Requirement method detect the quality of quinocetone in above-mentioned quinocetone premix, items refer to
Mark meets regulation.
The effect experiment of the present embodiment quinocetone premix：
1. with embodiment 1, the test period is 21 days for experimental animal, experiment packet, wherein：
Control group：30 piglets, only feed basal feed；
Test I groups：30 piglets, feed the folk prescription quinocetone premix 250g of basal feed+25%；
Test II groups：30 piglets, feed the quinocetone premix 250g of basal feed+the present embodiment；
2. result of the test
Record the result of 3 test groups and carry out statistical analysis, result of the test is shown in Table 7 and table 8, tries as can be seen from Table 7
Test I groups and the experiment increased weight of II group piglets is above control group, feedstuff-meat ratio is below control group, tests I groups and experiment II
The effect of group is similar；The diarrhea rate for testing I groups and experiment II group piglets as can be seen from Table 8 is below control group, but tests
The effect of II groups is more notable.Illustrate that quinocetone premix provided in this embodiment has significant drop to the diarrhea rate of weanling pig
It is low to act on and the production performance of piglet be further improved.
Influence of 7 quinocetone of table to piglet growth performance
Influence of 8 quinocetone of table to grice diarrhoea rate
| Group | Head number | Diarrhea rate, % |
| Control group | 30 | 18.7A |
| Test I groups | 30 | 13.47B |
| Test II groups | 30 | 11.9C |
| SEM | 0.7 |
Embodiment 5：
The embodiment provides a kind of quinocetone premix, wherein：Quinocetone content is 25%, and alkaline kation compound contains
Measure as 2.5%, precipitated calcium carbonate content is 72.5%.The preparation method of the present embodiment quinocetone premix, it is specific as follows：
Weigh 62.5g quinocetones, 6.25g alkaline kation compounds, the precipitated calcium carbonate of 181.25g；Weighed above-mentioned
Quinocetone, alkaline kation compound and precipitated calcium carbonate be together put into mixer be uniformly mixed, up to 250g quinocetones
Pre-mixing agent.
Foundation《Veterinary medical quality standard》Requirement method detect the quality of quinocetone in above-mentioned quinocetone premix, items refer to
Mark meets regulation.
The effect experiment of the present embodiment quinocetone premix：
1. experimental animal, experiment are grouped and the test period is with embodiment 4, wherein：
Control group：30 piglets, only feed basal feed；
Test I groups：30 piglets, feed the folk prescription quinocetone premix 250g of basal feed+25%；
Test II groups：30 piglets, feed the quinocetone premix 250g of basal feed+the present embodiment；
2. result of the test
Record the result of 3 test groups and carry out statistical analysis, result of the test is shown in Table 9 and table 10, tries as can be seen from Table 9
Test I groups and the experiment increased weight of II group piglets is above control group, feedstuff-meat ratio is below control group, but tests the effect of II groups
It is more notable；The diarrhea rate for testing I groups and experiment II group piglets as can be seen from Table 10 is below control group, but tests II groups
Effect is more notable.Illustrate that quinocetone premix provided in this embodiment is significantly reduced effect to the diarrhea rate of weanling pig
And the production performance of piglet can be further improved.
Influence of 9 quinocetone of table to piglet growth performance
| Group | Initial weight, kg | End weight, kg | Average daily gain, g | Average daily gain, g | Feedstuff-meat ratio |
| Control group | 7.44 | 14.17 | 320 | 461 | 1.44A |
| Test I groups | 7.64 | 14.75 | 339 | 482 | 1.42B |
| Test II groups | 7.38 | 14.7 | 348 | 478 | 1.38C |
| SEM | 0.23 | 0.56 | 10 | 18 | 0.01 |
Influence of 10 quinocetone of table to grice diarrhoea rate
| Group | Head number | Diarrhea rate, % |
| Control group | 30 | 18.7A |
| Test I groups | 30 | 13.47B |
| Test II groups | 30 | 11.6C |
| SEM | 0.7 |
Embodiment 6：
The embodiment provides a kind of quinocetone premix, wherein：Quinocetone content is 25%, and alkaline kation compound contains
Measure as 5%, precipitated calcium carbonate content is 70%.The preparation method of the present embodiment quinocetone premix, it is specific as follows：
Weigh 62.5g quinocetones, 12.5g alkaline kation compounds, the precipitated calcium carbonate of 175g；By the above-mentioned quinoline weighed
Ketenes, alkaline kation compound and precipitated calcium carbonate are together put into mixer and are uniformly mixed, and are premixed up to 250g quinocetones
Agent.
Foundation《Veterinary medical quality standard》Requirement method detect the quality of quinocetone in above-mentioned quinocetone premix, items refer to
Mark meets regulation.
The effect experiment of the present embodiment quinocetone premix：
1. experimental animal, experiment are grouped and the test period is with embodiment 4, wherein：
Control group：30 piglets, only feed basal feed；
Test I groups：30 piglets, feed the folk prescription quinocetone premix 250g of basal feed+25%；
Test II groups：30 piglets, feed the quinocetone premix 250g of basal feed+the present embodiment；
2. result of the test
Record the result of 3 test groups and carry out statistical analysis, result of the test is shown in Table 11 and table 12, as can be seen from Table 11
Experiment I groups and the experiment increased weight of II group piglets are above control group, and feedstuff-meat ratio is below control group, but tests the effect of II groups
Fruit is more notable；The diarrhea rate for testing I groups and experiment II group piglets as can be seen from Table 12 is below control group, but tests II groups
Effect it is more notable.Illustrate that quinocetone premix provided in this embodiment is significantly reduced work to the diarrhea rate of weanling pig
With and can further improve the production performance of piglet.
Influence of 11 quinocetone of table to piglet growth performance
| Group | Initial weight, kg | End weight, kg | Average daily gain, g | Average daily gain, g | Feedstuff-meat ratio |
| Control group | 7.44 | 14.17 | 320 | 461 | 1.44A |
| Test I groups | 7.64 | 14.75 | 339 | 482 | 1.42B |
| Test II groups | 7.58 | 15.05 | 355 | 483 | 1.36C |
| SEM | 0.23 | 0.56 | 10 | 18 | 0.01 |
Influence of 12 quinocetone of table to grice diarrhoea rate
| Group | Head number | Diarrhea rate, % |
| Control group | 30 | 18.7A |
| Test I groups | 30 | 13.47B |
| Test II groups | 30 | 10.5C |
| SEM | 0.7 |
By embodiment 1~6 it can be seen that the quinocetone premix of the technical program offer is than folk prescription quinocetone premix
Effect is more preferable, more notable to the effect of prevention animal diarrhea disease, can also further promote growth of animal and reduce material meat
Than.
The embodiment of present invention described above, is not intended to limit the scope of the present invention..Any basis
The various other corresponding changes and deformation that the technical concept of the present invention is made, should be included in the guarantor of the claims in the present invention
In the range of shield.
Claims (5)
1. a kind of quinocetone premix, it is characterised in that it includes quinocetone and alkaline kation compound.
2. quinocetone premix according to claim 1, it is characterised in that it further includes pharmaceutic adjuvant.
3. quinocetone premix according to claim 2, it is characterised in that the percentage by weight of the quinocetone is 5%
~25%, the percentage by weight of alkaline kation compound is 0.2%~5%, and surplus is pharmaceutic adjuvant.
4. quinocetone premix according to claim 3, it is characterised in that the percentage by weight of the quinocetone is 5%
Or 25%, the percentage by weight of alkaline kation compound is 0.2%~5%, and surplus is pharmaceutic adjuvant.
5. according to claim 2~4 any one of them quinocetone premix, it is characterised in that the pharmaceutic adjuvant is lightweight
Calcium carbonate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711187256.8A CN108029865A (en) | 2017-11-24 | 2017-11-24 | A kind of quinocetone premix |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711187256.8A CN108029865A (en) | 2017-11-24 | 2017-11-24 | A kind of quinocetone premix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108029865A true CN108029865A (en) | 2018-05-15 |
Family
ID=62093383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711187256.8A Pending CN108029865A (en) | 2017-11-24 | 2017-11-24 | A kind of quinocetone premix |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108029865A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109498597A (en) * | 2018-12-07 | 2019-03-22 | 佛山市正典生物技术有限公司 | A kind of quinocetone pellet and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214391B1 (en) * | 2000-02-18 | 2001-04-10 | Nel Biotech Co., Ltd. | Liquid feedstuff additives and preparation thereof |
| CN102232476A (en) * | 2011-08-15 | 2011-11-09 | 李庆林 | Ion physiological regulator for animals and preparation method thereof |
| CN104922074A (en) * | 2015-05-26 | 2015-09-23 | 浙江汇能动物药品有限公司 | Granular quinocetone premix and preparation method thereof |
-
2017
- 2017-11-24 CN CN201711187256.8A patent/CN108029865A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214391B1 (en) * | 2000-02-18 | 2001-04-10 | Nel Biotech Co., Ltd. | Liquid feedstuff additives and preparation thereof |
| CN102232476A (en) * | 2011-08-15 | 2011-11-09 | 李庆林 | Ion physiological regulator for animals and preparation method thereof |
| CN104922074A (en) * | 2015-05-26 | 2015-09-23 | 浙江汇能动物药品有限公司 | Granular quinocetone premix and preparation method thereof |
Non-Patent Citations (7)
| Title |
|---|
| 余平良等: ""巴尔麦氏"——无抗养猪专利产品", 《北方牧业》 * |
| 吴先华等: "多功能碱性阳离子及微生态制剂复合物对保育猪应用效果的研究", 《养猪》 * |
| 吴先华等: "巴尔麦氏在保育弱猪饲粮中的应用效果试验", 《养猪》 * |
| 张哲等: "巴尔吡尔对畜禽常见病原菌体外抑菌效果研究", 《黑龙江畜牧兽医》 * |
| 汪善锋等: "碱性阳离子复合物对断奶仔猪生长性能的影响", 《养猪》 * |
| 盛大远: "增强免疫的功能性饲料添加剂——巴罗顿", 《养殖技术顾问》 * |
| 胡功政等: "《新全实用兽药手册》", 30 September 2009, 河南科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109498597A (en) * | 2018-12-07 | 2019-03-22 | 佛山市正典生物技术有限公司 | A kind of quinocetone pellet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ponce et al. | Effects of dietary supplementation of a yeast product on performance and morbidity of newly received beef heifers | |
| Njagi et al. | Effects of dietary Yucca meal on growth, haematology, non‐specific immune responses and disease resistance of juvenile Nile tilapia, Oreochromis niloticus (Linnaeus, 1758) | |
| CN102247386A (en) | Soluble powder used for treating poultry coccidiosis | |
| CN101829082A (en) | Method for preparing veterinary injection of spectinomycin hydrochloride and lincomycin hydrochloride | |
| CN108029865A (en) | A kind of quinocetone premix | |
| KR101413184B1 (en) | Use of salts and herbal extracts mixture for the treatment of domestic animals and poultry | |
| EP3217971B1 (en) | Antiviral effects of narasin in swine feed | |
| CN108142688A (en) | A kind of child care material without zinc oxide | |
| CN102000092B (en) | New application of sulfadiazine sodium in preparing medicine for preventing or treating Bombyx mori septicemia | |
| Cusack | Effects of a dietary complex of humic and fulvic acids (FeedMAX 15™) on the health and production of feedlot cattle destined for the Australian domestic market | |
| CN101669959A (en) | Medical composite for treating livestock and poultry intestinal canal diseases and preparation method and application thereof | |
| EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) | Scientific Opinion on the safety and efficacy of Biosprint®(Saccharomyces cerevisisae) for piglets | |
| CN101966201A (en) | Compound norfloxacin nicotinic soluble powder and preparation method thereof | |
| CN104171498A (en) | Green feed additive capable of treating runt pig and using method thereof | |
| CN103783281A (en) | Health growth-promotion feed additive replacing antibiotic and preparation method thereof | |
| CN112998132A (en) | Composite antioxidant for animal feed and preparation method thereof | |
| EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) | Scientific Opinion on Miya‐Gold®(Clostridium butyricum) as a feed additive for weaned piglets, minor weaned porcine species and minor avian species | |
| Gole et al. | Studies on supplementation of peppermint essential oil and organic acids on performance and gut health of broilers | |
| CN103830254A (en) | Soluble powder for treating respiratory diseases of livestock and poultry | |
| EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) et al. | Safety and efficacy of a feed additive consisting of Bacillus subtilis FERM BP‐07462, Enterococcus lactis FERM BP‐10867 and Clostridium butyricum FERM BP‐10866 (BIO‐THREE®) for chickens for fattening, chickens reared for laying, turkeys for fattening, turkeys reared for breeding, all avian species for rearing/fattening to slaughter and all avian species reared for laying or breeding to point of lay (TOA BIOPHARMA Co., Ltd.) | |
| RU2471359C1 (en) | Method for correction of immunobiological indices with piglets in period of weaning | |
| Ladeira et al. | 132 Performance and carcass traits of Nellore and Nellore× Angus steers fed whole shelled corn diets | |
| CN102641500A (en) | Composite for preventing and curing diarrhea of piglets | |
| KR102480021B1 (en) | Composition for preventing and treating respiratory disease of livestock animal and treating method using the same | |
| CN102283906A (en) | Chinese medicinal composition for treating fox and raccoon bacterial enteritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180515 |